Biomarkers of AKI

Abstract

1. Holtzman. CSF Biomarkers for Alzheimer's Disease: current utility and potential future use. Neurobiol Aging (2011) 32:S4–S9 2. Hardy and Selkoe. The Amyloid Hypothesis of Alzheimer's Disease: progress and problems on the road to therapeutics. Science (2002) 297:353-356 3. Sunderland et al., Decreased β-Amyloid1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients with Alzheimer Disease. JAMA (2003) 289:2094-2103 4. Blennow and Hampel. CSF Markers for Incipient Alzheimer's Disease. Lancet Neurol (2003) 2:605-13 5. Blennow. Cerebrospinal Fluid Protein Biomarkers for Alzheimer 's disease. NeuroRx (2004) 1:213-25 6. Fagan et al., Inverse Relation between In Vivo Amyloid Imaging Load and Cerebrospinal Fluid Aβ42 in Humans. Ann Neurol (2006) 59:512-519 7. Fagan et al., Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Mol. Med. 1, 371-380 8. Fagan et al., Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 64:343-349 9. Tapiola et al., Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. Arch Neurol (2009) 66:382-389 10. Arai et al., Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res. Commun (1997) 236:262-264 11. Arai et al., CSF Phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol. (2000) 166:201-203 Why use cerebrospinal fluid biomarkers for AD dementia diagnosis? 1. McKhann et al., The Diagnosis of Dementia due to Alzheimer's Disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer Dement (2011) 7: 263-269 2. Bouman et al., New Research Criteria for the Diagnosis of Alzheimer's Disease Applied in a Memory Clinic Population. Dement Geriatr Cogn Disord (2010) 30: 1-7 3. Blennow and Hampel. CSF Markers for Incipient Alzheimer's Disease. Lancet Neurol (2003) 2:605-13 4. Blennow et al., CSF Biomarkers for Mild Cognitive Impairment. J Intern Med (2004) 256:224-234 5. Blennow et al., CSF Biomarkers for Alzheimer's Disease: use in early diagnosis and evaluation of drug treatment. Exper Rev Mol Diagn (2005) 5:661-672 6. Humpel . Identifying and Validating Biomarkers for Alzheimer's Disease. Trends Biotechnol (2011) 29(1):26-32 CSF biomarker analysis increases diagnostic certainty